Cargando…

AMCP Partnership Forum: Driving New Advances in Dyslipidemia Management

SUMMARY: Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors are specialty medications approved for the treatment of dyslipidemia. Because dyslipidemia is a prevalent and chronic condition, the costs associated with PCSK9 inhibitors must be carefully weighed against the benefits that they pr...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398088/
https://www.ncbi.nlm.nih.gov/pubmed/27023696
http://dx.doi.org/10.18553/jmcp.2016.22.4.426